These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 38870946)
21. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy. Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605 [TBL] [Abstract][Full Text] [Related]
22. CTLA4 blockade maximizes antitumor T-cell activation by dendritic cells presenting idiotype protein or opsonized anti-CD20 antibody-coated lymphoma cells. Hsu FJ; Komarovskaya M J Immunother; 2002; 25(6):455-68. PubMed ID: 12439343 [TBL] [Abstract][Full Text] [Related]
23. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma. Goldszmid RS; Idoyaga J; Bravo AI; Steinman R; Mordoh J; Wainstok R J Immunol; 2003 Dec; 171(11):5940-7. PubMed ID: 14634105 [TBL] [Abstract][Full Text] [Related]
24. Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine. Hassannia H; Ghasemi Chaleshtari M; Atyabi F; Nosouhian M; Masjedi A; Hojjat-Farsangi M; Namdar A; Azizi G; Mohammadi H; Ghalamfarsa G; Sabz G; Hasanzadeh S; Yousefi M; Jadidi-Niaragh F Immunology; 2020 Jan; 159(1):75-87. PubMed ID: 31587253 [TBL] [Abstract][Full Text] [Related]
25. Bypassing STAT3-mediated inhibition of the transcriptional regulator ID2 improves the antitumor efficacy of dendritic cells. Li HS; Liu C; Xiao Y; Chu F; Liang X; Peng W; Hu J; Neelapu SS; Sun SC; Hwu P; Watowich SS Sci Signal; 2016 Sep; 9(447):ra94. PubMed ID: 27678219 [TBL] [Abstract][Full Text] [Related]
26. NK cells are required for dendritic cell-based immunotherapy at the time of tumor challenge. Bouwer AL; Saunderson SC; Caldwell FJ; Damani TT; Pelham SJ; Dunn AC; Jack RW; Stoitzner P; McLellan AD J Immunol; 2014 Mar; 192(5):2514-21. PubMed ID: 24477907 [TBL] [Abstract][Full Text] [Related]
27. Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4 Beavis PA; Henderson MA; Giuffrida L; Davenport AJ; Petley EV; House IG; Lai J; Sek K; Milenkovski N; John LB; Mardiana S; Slaney CY; Trapani JA; Loi S; Kershaw MH; Haynes NM; Darcy PK Cancer Immunol Res; 2018 Sep; 6(9):1069-1081. PubMed ID: 30018045 [TBL] [Abstract][Full Text] [Related]
28. Dendritic cells stimulated with outer membrane protein A (OmpA) of Salmonella typhimurium generate effective anti-tumor immunity. Jang MJ; Kim JE; Chung YH; Lee WB; Shin YK; Lee JS; Kim D; Park YM Vaccine; 2011 Mar; 29(13):2400-10. PubMed ID: 21276440 [TBL] [Abstract][Full Text] [Related]
29. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells. Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056 [TBL] [Abstract][Full Text] [Related]
30. Generation of dendritic cell-based vaccine using high hydrostatic pressure for non-small cell lung cancer immunotherapy. Hradilova N; Sadilkova L; Palata O; Mysikova D; Mrazkova H; Lischke R; Spisek R; Adkins I PLoS One; 2017; 12(2):e0171539. PubMed ID: 28187172 [TBL] [Abstract][Full Text] [Related]
31. New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models. Lopes A; Bastiancich C; Bausart M; Ligot S; Lambricht L; Vanvarenberg K; Ucakar B; Gallez B; Préat V; Vandermeulen G J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795383 [TBL] [Abstract][Full Text] [Related]
32. CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination. Ahrends T; Bąbała N; Xiao Y; Yagita H; van Eenennaam H; Borst J Cancer Res; 2016 May; 76(10):2921-31. PubMed ID: 27020860 [TBL] [Abstract][Full Text] [Related]
33. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice. Wang B; Zaidi N; He LZ; Zhang L; Kuroiwa JM; Keler T; Steinman RM Breast Cancer Res; 2012 Mar; 14(2):R39. PubMed ID: 22397502 [TBL] [Abstract][Full Text] [Related]
34. CD40-activated B cells induce anti-tumor immunity in vivo. Wennhold K; Weber TM; Klein-Gonzalez N; Thelen M; Garcia-Marquez M; Chakupurakal G; Fiedler A; Schlösser HA; Fischer R; Theurich S; Shimabukuro-Vornhagen A; von Bergwelt-Baildon M Oncotarget; 2017 Apr; 8(17):27740-27753. PubMed ID: 26934557 [TBL] [Abstract][Full Text] [Related]
35. Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12. Homma S; Komita H; Sagawa Y; Ohno T; Toda G Immunology; 2005 Aug; 115(4):451-61. PubMed ID: 16011514 [TBL] [Abstract][Full Text] [Related]
36. Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells. Pruitt SK; Boczkowski D; de Rosa N; Haley NR; Morse MA; Tyler DS; Dannull J; Nair S Eur J Immunol; 2011 Dec; 41(12):3553-63. PubMed ID: 22028176 [TBL] [Abstract][Full Text] [Related]
37. Anti-CTLA-4 synergizes with dendritic cell-targeted vaccine to promote IL-3-dependent CD4 Zaidi N; Quezada SA; Kuroiwa JMY; Zhang L; Jaffee EM; Steinman RM; Wang B Ann N Y Acad Sci; 2019 Jun; 1445(1):62-73. PubMed ID: 30945313 [TBL] [Abstract][Full Text] [Related]
38. Significant anti-tumour activity of adoptively transferred T cells elicited by intratumoral dendritic cell vaccine injection through enhancing the ratio of CD8(+) T cell/regulatory T cells in tumour. Song S; Zhang K; You H; Wang J; Wang Z; Yan C; Liu F Clin Exp Immunol; 2010 Oct; 162(1):75-83. PubMed ID: 20735440 [TBL] [Abstract][Full Text] [Related]
39. Combination vaccine of dendritic cells (DCs) and T cells effectively suppressed preestablished malignant melanoma in mice. Asada H; Kishida T; Hirai H; Shin-Ya M; Imanishi J; Takeuchi M; Mazda O Cancer Lett; 2006 Aug; 240(1):83-93. PubMed ID: 16246489 [TBL] [Abstract][Full Text] [Related]
40. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine. Timmerman JM; Levy R J Immunol; 2000 May; 164(9):4797-803. PubMed ID: 10779787 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]